CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. Market Share Analysis
3.6. Value Chain Analysis
3.7. Regulatory Guidelines
3.8. Patent Landscape
CHAPTER 4: MEDICAL ISOTOPE MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Stable Isotopes
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Radioisotopes
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: MEDICAL ISOTOPE MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Diagonestic
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Nuclear Therapy
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: MEDICAL ISOTOPE MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Diagnostic Centers
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Research Institutes
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: MEDICAL ISOTOPE MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Type
7.2.3. Market size and forecast, by Application
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Type
7.2.5.1.2. Market size and forecast, by Application
7.2.5.1.3. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Type
7.2.5.2.2. Market size and forecast, by Application
7.2.5.2.3. Market size and forecast, by End User
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Type
7.2.5.3.2. Market size and forecast, by Application
7.2.5.3.3. Market size and forecast, by End User
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Type
7.3.3. Market size and forecast, by Application
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Type
7.3.5.1.2. Market size and forecast, by Application
7.3.5.1.3. Market size and forecast, by End User
7.3.5.2. UK
7.3.5.2.1. Market size and forecast, by Type
7.3.5.2.2. Market size and forecast, by Application
7.3.5.2.3. Market size and forecast, by End User
7.3.5.3. France
7.3.5.3.1. Market size and forecast, by Type
7.3.5.3.2. Market size and forecast, by Application
7.3.5.3.3. Market size and forecast, by End User
7.3.5.4. Russia
7.3.5.4.1. Market size and forecast, by Type
7.3.5.4.2. Market size and forecast, by Application
7.3.5.4.3. Market size and forecast, by End User
7.3.5.5. Italy
7.3.5.5.1. Market size and forecast, by Type
7.3.5.5.2. Market size and forecast, by Application
7.3.5.5.3. Market size and forecast, by End User
7.3.5.6. Rest of Europe
7.3.5.6.1. Market size and forecast, by Type
7.3.5.6.2. Market size and forecast, by Application
7.3.5.6.3. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Type
7.4.3. Market size and forecast, by Application
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. China
7.4.5.1.1. Market size and forecast, by Type
7.4.5.1.2. Market size and forecast, by Application
7.4.5.1.3. Market size and forecast, by End User
7.4.5.2. Japan
7.4.5.2.1. Market size and forecast, by Type
7.4.5.2.2. Market size and forecast, by Application
7.4.5.2.3. Market size and forecast, by End User
7.4.5.3. India
7.4.5.3.1. Market size and forecast, by Type
7.4.5.3.2. Market size and forecast, by Application
7.4.5.3.3. Market size and forecast, by End User
7.4.5.4. South Korea
7.4.5.4.1. Market size and forecast, by Type
7.4.5.4.2. Market size and forecast, by Application
7.4.5.4.3. Market size and forecast, by End User
7.4.5.5. Australia
7.4.5.5.1. Market size and forecast, by Type
7.4.5.5.2. Market size and forecast, by Application
7.4.5.5.3. Market size and forecast, by End User
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Market size and forecast, by Type
7.4.5.6.2. Market size and forecast, by Application
7.4.5.6.3. Market size and forecast, by End User
7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Type
7.5.3. Market size and forecast, by Application
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Type
7.5.5.1.2. Market size and forecast, by Application
7.5.5.1.3. Market size and forecast, by End User
7.5.5.2. Saudi Arabia
7.5.5.2.1. Market size and forecast, by Type
7.5.5.2.2. Market size and forecast, by Application
7.5.5.2.3. Market size and forecast, by End User
7.5.5.3. UAE
7.5.5.3.1. Market size and forecast, by Type
7.5.5.3.2. Market size and forecast, by Application
7.5.5.3.3. Market size and forecast, by End User
7.5.5.4. South Africa
7.5.5.4.1. Market size and forecast, by Type
7.5.5.4.2. Market size and forecast, by Application
7.5.5.4.3. Market size and forecast, by End User
7.5.5.5. Rest of LAMEA
7.5.5.5.1. Market size and forecast, by Type
7.5.5.5.2. Market size and forecast, by Application
7.5.5.5.3. Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Canadian Nuclear Laboratories (CNL)
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Curium
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. GE Healthcare
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Jubilant Radiopharma
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Nordion Inc.
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. IBA Radiopharma Solutions
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Mallinckrodt Pharmaceuticals
9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. northstar medical radioisotopes, llc
9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Eczacibasi-Monrol Nuclear Products
9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. Isotopen Technologien München (ITM)
9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.10.7. Key strategic moves and developments
| ※参考情報 医療用同位体は、主に放射線医療に利用される放射性同位体の一種です。これらの同位体は、診断や治療において非常に重要な役割を果たしており、特に放射線核医学の分野で広く用いられています。 医療用同位体の種類は多岐にわたりますが、その中でも特に有名なものには、テクネチウム-99m、ヨウ素-131、フッ素-18などがあります。テクネチウム-99mは、診断用イメージングで最も一般的に使用される同位体であり、特に心臓や骨のスキャンに利用されます。この同位体は、非常に短い半減期（約6時間）を持っているため、患者に与える放射線量が非常に少なく、安全性が高いとされています。ヨウ素-131は、甲状腺の疾患、特に甲状腺癌の治療に使われることが多く、体内で甲状腺に集まりやすい特性を持っています。フッ素-18は、ポジトロン断層法（PET）において、がんや神経疾患の診断に利用されています。この同位体は、がん細胞が高い代謝活動を示すことから、腫瘍の位置や大きさを把握するのに適しています。 医療用同位体の主な用途は、診断と治療の2つに大別されます。診断用途では、主に画像診断技術に利用され、患者の体内の状態を可視化するのに役立ちます。放射線を使用した画像診断には、シンチグラフィー、CTスキャン、PETスキャンなどがあります。シンチグラフィーは、特定の臓器の機能を評価するために、放射性トレーサーを用いて画像を取得する方法です。 治療用途では、特に癌治療において効果を発揮します。放射線治療は腫瘍を縮小させたり、癌細胞を破壊したりするために利用され、ヨウ素-131を用いた甲状腺癌の治療や、ストロンチウム-89を用いた骨転移の治療などがその代表例です。 医療用同位体の生成には、主に核反応を利用します。医療用同位体は、原子炉やサイクロトロンと呼ばれる加速器を使用して生産されます。原子炉では、ウランなどの核燃料を用いて中性子を生成し、これを放射性同位体に変える反応を行います。サイクロトロンでは、加速された粒子をターゲットに衝突させることで同位体を生成します。どちらの方法も、医療現場でのニーズに応じた規模や種類の同位体を効率よく生産することができます。 医療用同位体の利用には、一定の倫理的課題も伴います。特に放射線の健康への影響や、廃棄物の管理に関しては十分な配慮が必要です。また、供給の安定性も課題であり、発展途上国では医療資源が限られているため、同位体の入手が困難な場合もあります。このため、グローバルな供給チェーンの整備や、新たな同位体の開発が求められています。 近年では、医療用同位体の研究と利用が進化しており、より効率的で安全な方法が模索されています。新しい技術として、ターゲットの選択やアルゴリズムの発展により、より少ないリソースで効果的な同位体を生成する方法が開発されています。また、放射線の利用方法に関する新たなアプローチも研究されており、安全な診断と治療を提供できる可能性が広がっています。 最後に、医療用同位体は医療の進歩に多大な貢献をしており、今後もその重要性は増していくことが予想されます。未来の医療において、放射線医療の役割がさらに強化されることは間違いありません。医療用同位体の研究と利用の進展が、より多くの患者に希望をもたらすことを期待しています。 |
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
